Insulet stock shed its early gains Thursday, sliding into the red, despite broadly beating sales forecasts for its insulin ...

Q3 2025 Management View CEO Ashley McEvoy welcomed Flavia Pease as the new CFO and announced Eric Benjamin's promotion to COO and the appointment of Manoj Raghunandanan as Chief Growth Officer. McEvoy ...

Medical device maker Insulet on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin pumps, which eliminate the need for daily ...

Following the strong performance, Insulet raised its full-year 2025 revenue growth guidance to 28-29% in constant currency, up from its previous outlook of 24-27%. The company also increased its gross ...

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...

Insulet is bringing a splash of color to the diabetes technology market. Working with Pantone, the insulin pump company has created the “bright and joyful tropical orange yellow” color Omnipod Mango.

Insulet PODD appears well-poised on solid prospects in the diabetes market. The company continues to gain from strong Omnipod 5 and Omnipod DASH uptake globally. The stock carries a Zacks Rank #1 ...

Insulet Corporation’s PODD Omnipod and Omnipod DASH insulin management systems recently received FDA’s approval for their use with Eli Lilly and Company’s LLY Lyumjev (insulin lispro-aabc injection) ...

The Omnipod 5 System consists of a tubeless wearable Pod, the Omnipod 5 mobile app, and the Dexcom G6 Continuous Glucose Monitoring System. The Food and Drug Administration (FDA) has cleared the ...

The news this week that the Omnipod insulin pump had finally received Medicare coverage brought cheers from diabetes advocates and physicians alike—at long last, the popular tubeless device might soon ...